

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Broncus Holding Corporation**

### **堃博医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2216)**

## **(I) RE-DESIGNATION OF DIRECTOR (II) CHANGE OF CHIEF EXECUTIVE OFFICER**

The Board announces that with effect from September 1, 2023:

1. Mr. Guowei Zhan will be re-designated from an executive Director to a non-executive Director; and
2. Mr. Hong Xu will be appointed as the Chief Executive Officer of the Company in place of Mr. Guowei Zhan.

### **RE-DESIGNATION OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**” and each, a “**Director**”) of Broncus Holding Corporation (the “**Company**”) announces that Mr. Guowei Zhan (“**Mr. Zhan**”) has been re-designated (the “**Re-designation**”) from an executive Director to a non-executive Director with effect from September 1, 2023, as he would like to devote more time to his other commercial and personal affairs.

The biographical details of Mr. Zhan are as follows:

**Mr. Guowei Zhan** (湛國威), aged 47, was appointed as an executive Director on May 6, 2021. He joined our Group as a General Manager and was also appointed as the Chief Executive Officer of the Company in December 2017. He is mainly involved in overall strategic planning, business direction and operational management.

Mr. Zhan has over 23 years of experience in the industry of medical devices. Prior to joining the Group, Mr. Zhan was the vice president of DiNovA Medtech Technology Co., Ltd. (杭州德諾科技有限公司), a specialized medical device business incubator in China, from August 2015 to June 2017.

Mr. Zhan graduated with a bachelor’s degree in international finance from Sun Yat-sen University, China in June 1999.

In respect of the Re-designation, the Company will enter into a new service contract with Mr. Zhan in relation to his appointment as a non-executive Director for a term of one year commencing from September 1, 2023, subject to retirement by rotation and re-election at general meetings. Mr. Zhan will not receive director's fee from the Company during his tenure as a non-executive Director.

Mr. Zhan has confirmed that he had no disagreement with the Board and there were no matters relating to his Re-designation that should be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or the Stock Exchange.

As at the date of this announcement, Mr. Zhan was interested in 4,788,596 ordinary shares which represented approximately 0.91% of the number of the total issued shares of the Company.

Save as disclosed above, Mr. Zhan has confirmed that as at the date of this announcement, (i) he did not hold any other positions with the Company and other members of the Group (ii) he did not hold any other directorships in any listed public companies in the last three years; (iii) he did not have any relationships with any Directors, senior management, substantial Shareholders or controlling Shareholders; and (iv) he did not have any other interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to the Re-designation of Mr. Zhan that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules nor any matters that need to be brought to the attention of the Shareholders.

## **CHANGE OF CHIEF EXECUTIVE OFFICER**

The Board is pleased to announce that it has resolved to change the chief executive officer of the Company (the “**Chief Executive Officer**”) from Mr. Zhan to Mr. Hong Xu (“**Mr. Xu**”), with effect from September 1, 2023, as Mr. Zhan would like to devote more time to his other commercial and personal affairs. Mr. Xu will be responsible for the Company's overall strategic planning and business direction.

The biographical details of Mr. Xu are as follows:

**Mr. Hong XU (徐宏)**, aged 37, was appointed as an executive Director and the chief technology officer of our Company (“**CTO**”) on May 6, 2021. He joined our Group as the chief technology officer of Hangzhou Broncus Medical Co., Ltd.\* (杭州堃博生物科技有限公司, a subsidiary of the Company and hereinafter as “**Broncus Hangzhou**”) in February 2018. As at the date of this announcement, Mr. Xu has applied for more than 600 patents as an inventor. In June 2022, Mr. Xu obtained the qualification certificate issued by the Zhejiang Province Bureau of Human Resources and Social Security in the field of medical devices, and obtained the title of “senior engineer”.

Mr. Xu has over 12 years of industry experience. Prior to joining our Group, Mr. Xu served as the associate general manager at Shenzhen Chuangling Image Technology Co., Ltd. (深圳市創領圖像技術有限公司), a subsidiary of APT Medical Inc. (深圳惠泰醫療器械股份有限公司), an electrophysiological and vascular interventional medical device company from September 2014 to February 2018 and held positions of manager of R&D, associate manager of R&D department and R&D engineer at APT Medical Inc. from July 2010 to March 2015.

Mr. Xu obtained a bachelor's degree in polymer material and engineering from Sichuan University in Chengdu, China, in June 2010.

Mr. Xu currently serves as a legal representative and manager in a number of major subsidiaries of our Group, including Broncus Hangzhou, Broncus Medical (China) Co., Ltd.\* (堃博生物科技(上海)有限公司) and Hangzhou Kunpeng Medical Co., Ltd.\* (杭州堃鵬生物科技有限公司).

As the date of this announcement, Mr. Xu's current remuneration will be RMB70,000 per month and bonus will be payable at the discretion of the Board with reference to his performance, experience, and responsibilities, as well as the prevailing market conditions.

As at the date of this announcement, Mr. Xu was interested in 1,505,912 ordinary shares which represented approximately 0.29% of the number of total issued shares of the Company.

Save as otherwise disclosed, Mr. Xu has confirmed that as at the date of this announcement, (i) he did not hold any other positions with the Company and other members of the Group; (ii) he did not have any relationships with any Directors, senior management, substantial Shareholders or controlling Shareholders; (iii) he did not hold any other directorships in any listed public companies in the last three years or have any other major appointments or professional qualifications; and (iv) he did not have any other interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to the appointment of Mr. Xu that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules nor any matters that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its gratitude to Mr. Zhan for his valuable contribution to the Company during his tenure of service as an executive Director and the Chief Executive Officer, and to welcome Mr. Xu on his new appointment.

By Order of the Board  
**Broncus Holding Corporation**  
**ZHAO Michael Yi Wei**  
*Chairman*

Hong Kong, August 29, 2023

*As of the date of this announcement, the Board comprises Mr. Guowei Zhan and Mr. Hong Xu as executive Directors, Mr. Michael Yi Wei Zhao, Mr. Zhenjun Zi and Mr. Ao Zhang as non-executive Directors, and Dr. Pok Man Kam, Professor Joseph Wan Yee Lau and Ms. Yee Sin Wong as independent non-executive Directors.*

*\* for identification purposes only.*